@MirzaCPH
Joined May 2016
  • Tweets34
  • Following8
  • Followers287
9Media
Exciting data! ENGOT is proud to be enrolling the XPORT-EC-042trial. #esgo2024
MSKCC Team Uterus@TeamEndo_MSK7 Mar 2024
Is selinexor the magic drug in NSMP endometrial cancer ? #esgo2024 An engaging discussion by Dr Sehouli
1
1
1
14
2,692
📢👏🏻🏆Congratulations to @MirzaCPH and the #RUBYtrial team and to patients who hopefully will can benefit from #immuntherapy💉🏥🧪 in advanced #endometrialcarcinoma – at Tampa, FL
Ane Gerda Z Eriksson MD PhD@agz_eriksson27 Mar 2023
Replying to @MirzaCPH
@MirzaCPH presenting practice changing Ruby trial results at #SGOmtg ✅Dostarlimab +Carbo/Taxol in advanced&recurrent #EndometrialCancer ✅2yr PFS dMMR 61.4% HR0.28(95%CI 0.16-0.49) ✅2yr OS dMMR 83.3% HR0.30(95%CI 0.13-0.7) ✅dMMR ORR 77.6% w durable response & well-tolerated
1
12
2,280
Mansoor Mirza retweeted
NSGO_org@nsgo_org27 Mar 2023
𝐄𝐍𝐆𝐎𝐓, 𝐍𝐒𝐆𝐎-𝐂𝐓𝐔 & 𝐆𝐎𝐆 𝐩𝐫𝐨𝐮𝐝𝐥𝐲 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐞 𝐠𝐫𝐨𝐮𝐧𝐝-𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐨𝐟 𝐄𝐍𝐆𝐎𝐓-𝐄𝐍6-𝐍𝐒𝐆𝐎/𝐆𝐎𝐆-3031/𝐑𝐔𝐁𝐘 𝐭𝐫𝐢𝐚𝐥. rb.gy/sqxq7u #Endometrial #Cancer #RUBY #NSGO #ENGOT #Dostarlimab #ESMO #SGO
3
1
10
1,579
Replying to @MirzaCPH
@MirzaCPH presenting practice changing Ruby trial results at #SGOmtg ✅Dostarlimab +Carbo/Taxol in advanced&recurrent #EndometrialCancer ✅2yr PFS dMMR 61.4% HR0.28(95%CI 0.16-0.49) ✅2yr OS dMMR 83.3% HR0.30(95%CI 0.13-0.7) ✅dMMR ORR 77.6% w durable response & well-tolerated – at Tampa, FL
2
17
2
43
5,592
Mansoor Mirza retweeted
NEJM
@NEJM27 Mar 2023
#SGOMtg: A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free survival of 61.4% with dostarlimab and 15.7% with placebo. Read full results of RUBY trial: nej.md/40lFbBN
Shown are Kaplan–Meier estimates of progression free survival in the population with mismatch repair–deficient (dMMR), microsatellite instability–high (MSI-H) disease

ALT Shown are Kaplan–Meier estimates of progression free survival in the population with mismatch repair–deficient (dMMR), microsatellite instability–high (MSI-H) disease

1
51
10
115
60,628
Mansoor Mirza retweeted
Annie Ellis@Stigetta27 Mar 2023
Endometrial cancer patient @researchmatters thanks @SGO_org for all the hard work. Standing ovation!! #SGOmtg #PatientsPurposeProgress #gyncsm
2
9
50
3,337
Amazing @ESGO_society esgo Council evening
1
3
1
18
2,510
The A team
NSGO_org@nsgo_org19 Dec 2022
Happy Holidays from NSGO-CTU 🎄
2
541
Mansoor Mirza retweeted
NSGO_org@nsgo_org19 Dec 2022
Happy Holidays from NSGO-CTU 🎄
1
1
3
813
@thxtomyfriends
1
9
EMA London
1
ESMO 2017 Highlights in Gynaecological Cancers: Hight Quality Data From Randomised Trials - YouTube m.youtube.com/watch?v=cIEQ03…
1
1
1
Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian Cancer shar.es/1V17g0 via @onclive
1
Mansoor Mirza retweeted
IGCS
@IGCSociety12 Sep 2017
Niraparib maintains quality of life in recurrent #ovariancancer bit.ly/2gWaAtV
5
1
7
Dr. Mirza @MirzaCPH from @Rigshospitalet on #ovariancancer xitter.cf/ascopost/status/907296…
The ASCO Post@ASCOPost11 Sep 2017
Mansoor Mirza, MD: Ovarian Cancer Treatment and Quality of Life ascopost.com/videos/2017-esm… #gyncsm #ESMO17 #oncology
1
1
"Mansoor Mirza, MD: Ovarian Cancer Treatment and Quality of Life" ascopost.com/videos/2017-esm… #oncology via @ascopost
"Olaparib Maintenance in Ovarian Cancer: Outcomes Reconsidered" ascopost.com/issues/april-25… via @ascopost
1
2
Niraparib (ZEJULA) fda.gov:80/FDAgov/Drugs/Info…
3
2
#SGOmtg @temkins @bpothuri
1
1
#SGOmtg visiting with friends
1
Load more